Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Flaherty

Showing results (451-460 of 580) with videos related to

Pageof 58
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging databaseJohn F Thompson, Seng-Jaw Soong, Charles M Balch, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 18, 2018
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapyXin Hong, Ryan J Sullivan, Mark Kalinich, et al.
The New England Journal of Medicine|October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsKeith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Journal of Cellular Biochemistry|April 20, 2021
Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulationVan T Hoang, Margarite D Matossian, Jacqueline La, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1CMark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge ConferenceMichael B Atkins, Marc S Ernstoff, Robert A Figlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Final version of 2009 AJCC melanoma staging and classificationCharles M Balch, Jeffrey E Gershenwald, Seng-Jaw Soong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol HApril K S Salama, Shuli Li, Erin R Macrae, et al.
Nature|November 25, 2011
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Poulikos I Poulikakos, Yogindra Persaud, Manickam Janakiraman, et al.
Pageof 58

Showing results (451-460 of 580) with videos related to

Sort By:
Pageof 58
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging databaseJohn F Thompson, Seng-Jaw Soong, Charles M Balch, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 18, 2018
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapyXin Hong, Ryan J Sullivan, Mark Kalinich, et al.
The New England Journal of Medicine|October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsKeith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Journal of Cellular Biochemistry|April 20, 2021
Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulationVan T Hoang, Margarite D Matossian, Jacqueline La, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1CMark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge ConferenceMichael B Atkins, Marc S Ernstoff, Robert A Figlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Final version of 2009 AJCC melanoma staging and classificationCharles M Balch, Jeffrey E Gershenwald, Seng-Jaw Soong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol HApril K S Salama, Shuli Li, Erin R Macrae, et al.
Nature|November 25, 2011
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Poulikos I Poulikakos, Yogindra Persaud, Manickam Janakiraman, et al.
Pageof 58